معرفی
Dr. Thomas McWilliams is an Associate Professor in the Department of Anatomy at the University of Helsinki, where he serves as Principal Investigator of the McWilliams Lab. He holds the title of Docent in Neurobiology and is an Academy of Finland Research Fellow. His work focuses on mitochondrial medicine and autophagy pathways, with particular emphasis on their roles in neurological health and disease. He supervises doctoral students in the Brain & Mind program and collaborates extensively with international research teams.
Dr. McWilliams' research interests span multiple interconnected fields:
- Neuroscience, with focus on Parkinson's Disease, dopaminergic neurons, and neurodegeneration
- Molecular and cellular mechanisms of autophagy and mitophagy
- Mitochondrial signaling and organelle crosstalk in mammalian tissues
- Molecular genetics of cellular degradation pathways
- Metabolism and its regulation in neuronal health and disease
His laboratory employs advanced molecular cell biology, biochemistry, and microscopy techniques using primary mouse neurons, human iPS-derived neurons, and sophisticated mouse genetics. The lab also utilizes multi-OMICs approaches in collaboration with core facilities for single-cell analytics and metabolomics.
Dr. McWilliams' publication record demonstrates consistent productivity with 35 research outputs over the past decade. His recent work shows increasing focus on longitudinal studies of autophagy in brain aging, the genetic basis of autophagy disorders, and metabolic regulation of mitochondrial quality control pathways. His research bridges basic cellular mechanisms with clinical applications in neurodegenerative diseases.
Scientific recognition includes four prestigious journal cover images:
- Journal of Cell Biology (2016)
- FEBS Journal (2018)
- Open Biology (2018)
- Current Opinion in Cell Biology (2017)
Dr. McWilliams actively mentors the next generation of scientists through in-depth training in his laboratory and supervision of doctoral students. He has secured significant research funding including a €1.1 million grant from Jane ja Aatos Erkon säätiö (2024-2028), funding from Instrumentariumin tiedesäätiö (2024), and support from Päivikki ja Sakari Sohlbergin säätiö (2023-2024). He also participates in the Research Council of Finland's University Profile project through 2030.
The McWilliams Lab maintains strong international collaborations and utilizes advanced core facilities in Helsinki for single-cell analytics and metabolomics. The lab's work has important implications for understanding and treating neurodegenerative conditions through targeting cellular quality control mechanisms.
